Механизмы воздействия антибиотиков на кишечник, роль Энтерола в профилактике и лечении антибиотик-ассоциированной диареи у детей


Корниенко Е.А.

Санкт-Петербургская государственная педиатрическая медицинская академия, Санкт-Петербург
Обсуждается проблема возникновения, диагностики и лечения антибиотико-ассоциированной диареи (ААД). Дана характеристика основных клинических форм ААД и принципы ее диагностики у детей. В случае появления диареи на фоне курса антибиотикотерапии, если возможно, необходимо отменить применяемый антибиотик. При любой из клинических форм ААД показано назначение пробиотиков, в случае необходимости продолжения антибиотикотерапии по поводу основной патологии производят смену антибиотика на менее опасный. Среди известных пробиотиков только два доказали свою эффективность в лечении ААД: Saccharomyces boulardii (Энтерол) и Lactobacillus rhamnosus GG (LGG). Однако сравнительные данные по изучению результатов лечения ААД этими пробиотиками показали, что S. boulardii превосходят LGG по эффективности.

Литература



  1. Bartlett JG. Antibiotic-associated diarrhea. Clin Infect Dis 1992;15:573–81.

  2. Beaugerie L, Flahault A, Barbut F, et al. Antibiotic-associated diarrhea and Clostridium difficile in the community. Aliment Pharmacol Ther 2003;17:905–12.

  3. Bouhnik Y, Rambaut JC, Buts JP, ets. Microflora and diarrhoea: antibiotic-associated diarrhoea. Gut Microflora. 2006;181–197.

  4. Wistrom J, Norrby SR, Myhre EB, et al. Frequency of antibiotic-associated diarrhoea in 2,462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother 2001;47:43–50.

  5. McFarland LV, Brandmarker SA, Guandalini S. Pediatric Clostridium difficile: a phantom menace or clinical reality? J Pediatr Gasroenterol Nutr 2000;31:220–31.

  6. Delmee M, Verellen G, Avesani V, et al. Clostridium difficile in neonates: serogrouping and epidemiology. Eur J Pediatr 1988; 147:36–40.

  7. Larson HE, Barclay FE, Honour P, et al. Epidemiology of Clostridium difficile in infants. J Infect Dis 1982;146:727–33.

  8. Ferroni A, Merckx J, Ancelle T, et al. Nosocomial outbreak of Clostridium difficile diarrhea in a pediatric service. Eur J Clin Microbiol nfect Dis 1997;16:928–33.

  9. Rambaud JC, LaMont JT, Buts JP. The clinical significance of Clostridium difficile infections in infants and children. 1996;29–36.

  10. Benoit R, Danquechin DE, Loulergue J, et al. Diarroea post-antibiotique : role de Klebsiella oxytoca. Gasroenterol Clin Biol 1992; 16:860–64.

  11. Rambaud JC, LaMont JT, Lamont JT. Recent advances in the structures and function of Clostridium difficile toxins. 1996;72–86.

  12. Price AB. Pseudomembranous colitis. 2005; 15–172.

  13. Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile-associatied diarrhea: a review. Arch Intern Med 2000;161(525):5–33.

  14. Rambaud JC, Ducluzeau R, Cooperstock M. Clostridium difficile in infants and children. 1990;81–94.

  15. Harris PR, Figueroa-Colon R. Rectal prolapse in children associated with Clostridium difficile infection. Pediatr Infect Dis J 1995;14:78–80.

  16. Garlani MJ, Murray JC, Morad AB, et al. Chronic osteomyelitis caused by Clostridium difficile in an adolescent with sickle cell disease. Pediatr Infect Dis J 1996;15:1054–56.

  17. Thomas DFM, Fernie DS, Bayston R, et al. Clostridial toxins in neonatal necrotising enterocolitis. Arch Dis Child 1984;59:270–83.

  18. Cetina-Sauri G, Sierra Basto G. Therapeutic evaluation of Saccharomyces boulardii in children with acute diarrhea. Annales de Pediatrie 1994;41(6):397–400.

  19. Castaneda C, Garcia E, Santa Cruz M, et al. Effects of Saccharomyces boulardii in children with chronic diarrhea, especially cases due to giardiasis. Revista Mexicana de Puericultura y Pediatria 1995;2:12.

  20. Castagliuolo I, LaMont JT, Nikulasson ST, et al. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infection and Immunity 1996; 12:5225–32.

  21. Gedek BR. Adherence of E.coli serogroup O-157 and the Salmonella typhimurium mutant DT 104 to the surface of Saccharomyces boulardii. Mycoses 1999;42(4):261–64.

  22. Cherucka D, Dahan S, Mograbi B, et al. Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells. Infection and Immunity 2000;68:5998–6004.

  23. Dahan S, Dalmasso G, Imbert V, et al. Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells. Infection and Immunity 2003;72(2):766–73.

  24. Buts JP, Bernasconi P, Van Craymest MP, et al. Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatric Research 1986; 20:192–96.

  25. Sougiolzis S. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kB-mediated IL-8 gene expression. Biochem Biophys Res Commun 2006;2:23.

  26. Girard-Pipau F, Pompei A, Schneider S, et al. Intestinal microflora, short chain and cellular fatty acids, influence of a probiotic Saccharomyces boulardii. Microb Ecolog in Health Dis 2002;14:220–27.

  27. Buts JP, Corthier G, Delmee M. Saccharomyces boulardii for Clostridium difficile- associated entheropathies in infants. J Pediatr Gastroenterol Nutr 1993;16:419–25.

  28. Costalos C, Skouteri V, Gounaris A, et al. Enteral feeding of premature infants with Saccharomyces boulardii. Early Hum Dev 2003; 11:89–96.


Похожие статьи


Бионика Медиа